세계의 뇌졸중 치료제 시장 : 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Stroke Therapeutics Market was valued at USD 16.6 billion in 2024 and is estimated to grow at a CAGR of 8.2% to reach USD 36.4 billion by 2034, fueled by the rising elderly population, coupled with increased prevalence of risk factors like obesity, hypertension, sedentary lifestyles, and chronic illnesses such as diabetes. An aging demographic is especially susceptible to stroke, leading to greater demand for advanced pharmaceutical treatments. At the same time, increased public health awareness and stronger government initiatives around early diagnosis and prevention are accelerating the adoption of therapeutics.

Pharmaceutical firms invest in research and development, focusing on novel biologics, gene therapies, and targeted drugs designed to improve clinical outcomes. Personalized medicine is becoming a key area of interest, allowing for more precise and effective treatment approaches. Stroke therapeutics includes medications, from antiplatelet agents and anticoagulants to thrombolytics and neuroprotective drugs. Substantial financial backing for R&D is helping expand the development pipeline, with new therapies aimed at improving outcomes for both ischemic and hemorrhagic stroke types.

Ischemic stroke, which occurs when a blood vessel to the brain is blocked, dominates the therapeutic market. This segment generated USD 13.1 billion in 2024 and is forecasted to hit USD 28.5 billion by 2034, growing at a CAGR of 8.1%. Given that ischemic strokes account for the majority of total cases globally, this demand trajectory remains strong. The rising prevalence of contributing conditions like high cholesterol, atrial fibrillation, and diabetes continues to push the need for more effective treatments. Drug innovations, especially in thrombolytic therapy and antiplatelet development, are helping improve survival rates and recovery outcomes.

When segmented by age group, individuals aged 60 and above have the largest share at 46.8% in 2024. The risk of stroke significantly increases with age due to declining vascular health and common comorbidities. Aging also affects neurovascular responsiveness, making seniors a key demographic for therapeutic intervention. The ongoing improvement of healthcare infrastructure and age-focused health initiatives are expected to sustain segment growth through 2034.

United States Stroke Therapeutics Market was valued at USD 6.5 billion in 2024, supported by advanced healthcare systems, high R&D intensity, and strong pharmaceutical presence. Rapid innovations, including stem cell therapies and AI-based diagnostic integration, reinforce the country's leadership. The growing focus on precision medicine and digital health platforms is further enhancing early detection and improving treatment efficacy. Robust public and private sector collaboration is fueling the expansion of clinical trials and pipeline development.

Key players such as Lupin, Pfizer, Boehringer Ingelheim, Sanofi, Genentech, Novartis, Bayer, AstraZeneca, Daiichi Sankyo, Johnson & Johnson Services, Cadrenal Therapeutics, Prestige Consumer Healthcare, Merck, Eisai, and Bristol-Myers Squibb are adopting aggressive growth strategies. These include expanding clinical pipelines, forming R&D partnerships, pursuing regulatory approvals for breakthrough drugs, and exploring personalized medicine to deliver targeted therapies. Many invest in AI platforms and biologics innovation to optimize treatment delivery and patient outcomes.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising stroke incidence cases
    • 3.2.1.2 Advancement in drug development
    • 3.2.1.3 Growing awareness and early diagnosis
    • 3.2.1.4 Rising investment in stroke research and government funding
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Strict regulatory approvals
    • 3.2.2.2 Side effects and safety concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Stroke Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Ischemic stroke
• 5.3 Hemorrhagic stroke
• 5.4 Other stroke types

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Tissue plasminogen activators (TPA)
• 6.3 Antiplatelet agents
• 6.4 Anticoagulants
• 6.5 Other drug classes

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Below 40
• 7.3 41-59
• 7.4 above 60

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals and clinics
• 8.3 Ambulatory surgical centers (ASCs)
• 8.4 Rehabilitation centers
• 8.5 Research and academic institutions

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 AstraZeneca
• 10.2 Bayer
• 10.3 Boehringer Ingelheim
• 10.4 Bristol-Myers Squibb (BMS)
• 10.5 Cadrenal Therapeutics
• 10.6 Daiichi Sankyo
• 10.7 Eisai
• 10.8 Genentech
• 10.9 Johnson & Johnson Services
• 10.10 Lupin
• 10.11 Merck
• 10.12 Novartis
• 10.13 Pfizer
• 10.14 Prestige Consumer Healthcare
• 10.15 Sanofi